top of page
About
Home
Team
Partnerships
Send us your innovation
Contact
EN
JP
We are an asset-light, emerging commercial-stage biopharma and MedTech venture that in-licenses early, de-risked assets to commercialize in Japan and the APAC region
News & Updates
NKGen and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan July 21, 2025
HekaBio Enters Strategic Partnership with Alfresa Holdings Corporation June 16, 2025
HekaBio Welcomes Deron Wolfe as Chief Financial Officer June 10, 2025
Rodney Kelly Joins HekaBio as Chief Growth Officer April 1, 2025
Dr. Yoshimura at the Institute of Science Tokyo has published "Efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for head and neck cancer recurrence after radiotherapy." Feb. 26
Limaca's Precision-GI™ Enters US Market Feb. 20, 2025
Limaca's Precision-GI™ Granted CMS Transitional Pass-Through (TPT) Payment Nov. 8, 2024
Serpin Pharma and HekaBio Sign Term Sheet for Groundbreaking Neuropathy Treatment July 9, 2024
Terrapeutics Pharma Partners with HekaBio K.K. to Bring Revolutionary Drug Discovery Platform to Japan June 19, 2024
1
2
3
4
bottom of page
